Nuveen Asset Management, LLC Madrigal Pharmaceuticals, Inc. Transaction History

Nuveen Asset Management, LLC

$345 Billion
Q3 2024

A detailed history of Nuveen Asset Management, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 88,994 shares of MDGL stock, worth $27.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

88,994

Previous 80,799 10.14%

Holding current value

$27.4 Million

Previous $22.6 Million 16.57%

% of portfolio

0.01%

Previous 0.01%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$212.22 - $292.96 $1.74 Million - $2.4 Million	8,195 Added 10.14%	88,994 $18.9 Million
Q2 2024 Aug 09, 2024	BUY	$193.33 - $291.99 $1.95 Million - $2.95 Million	10,087 Added 14.26%	80,799 $22.6 Million
Q1 2024 May 13, 2024	BUY	$171.37 - $283.23 $1.86 Million - $3.07 Million	10,840 Added 18.11%	70,712 $18.9 Million
Q4 2023 Feb 14, 2024	BUY	$120.4 - $237.13 $2.45 Million - $4.82 Million	20,337 Added 51.44%	59,872 $13.9 Million
Q3 2023 Nov 14, 2023	SELL	$146.04 - $225.78 $1.3 Million - $2.02 Million	-8,927 Reduced 18.42%	39,535 $5.77 Million
Q2 2023 Aug 14, 2023	BUY	$203.88 - $312.0 $2.49 Million - $3.82 Million	12,236 Added 33.78%	48,462 $11.2 Million
Q1 2023 May 15, 2023	SELL	$231.06 - $307.08 $125,696 - $167,051	-544 Reduced 1.48%	36,226 $8.78 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $90,446 - $459,340	1,549 Added 4.4%	36,770 $2.35 Million
Q3 2022 Nov 14, 2022	BUY	$60.57 - $79.51 $12,416 - $16,299	205 Added 0.59%	35,221 $2.29 Million
Q2 2022 Aug 15, 2022	BUY	$58.04 - $100.2 $109,521 - $189,077	1,887 Added 5.7%	35,016 $2.51 Million
Q1 2022 May 16, 2022	SELL	$55.89 - $101.89 $1.32 Million - $2.4 Million	-23,585 Reduced 41.59%	33,129 $3.14 Million
Q4 2021 Feb 14, 2022	SELL	$72.34 - $95.09 $692,076 - $909,726	-9,567 Reduced 14.43%	56,714 $4.05 Million
Q3 2021 Nov 12, 2021	BUY	$78.35 - $105.02 $471,118 - $631,485	6,013 Added 9.98%	66,281 $5.42 Million
Q2 2021 Aug 16, 2021	BUY	$97.2 - $137.59 $2.78 Million - $3.94 Million	28,627 Added 90.47%	60,268 $5.87 Million
Q1 2021 May 17, 2021	SELL	$108.54 - $125.2 $3,256 - $3,756	-30 Reduced 0.09%	31,641 $3.7 Million
Q4 2020 Feb 16, 2021	SELL	$110.06 - $133.7 $189,303 - $229,963	-1,720 Reduced 5.15%	31,671 $3.52 Million
Q3 2020 Nov 16, 2020	BUY	$99.78 - $124.21 $25,942 - $32,294	260 Added 0.78%	33,391 $3.96 Million
Q2 2020 Aug 14, 2020	SELL	$60.13 - $125.71 $163,613 - $342,056	-2,721 Reduced 7.59%	33,131 $3.75 Million
Q1 2020 May 14, 2020	BUY	$66.76 - $93.49 $178,850 - $250,459	2,679 Added 8.08%	35,852 $2.39 Million
Q4 2019 Feb 14, 2020	SELL	$84.28 - $118.5 $57,478 - $80,817	-682 Reduced 2.01%	33,173 $3.02 Million
Q3 2019 Nov 14, 2019	BUY	$84.4 - $106.53 $110,057 - $138,915	1,304 Added 4.01%	33,855 $2.92 Million
Q2 2019 Aug 15, 2019	BUY	$91.13 - $142.5 $2.97 Million - $4.64 Million	32,551 New	32,551 $3.41 Million

Others Institutions Holding MDGL

# of Institutions

297

Shares Held

22M

Call Options Held

819K

Put Options Held

640K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.28B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Madrigal Pharmaceuticals, Inc. Transaction History